TopologView all posts »
Novel anticoagulants: Is this the best we can do?Sep 12, 2011 11:45 EDT
Despite being a positive and significant trial, ARISTOTLE demonstrated the benefit of apixaban compared with warfarin in only 29 patients out of 1000. What about the remaining 971 people?
In an era of healthcare crisis and prolonged economic uncertainty, does the small margin of benefit shown in trials such as ARISTOTLE, RE-LY, and ROCKET-AF justify their cost?
What are your thoughts on the role of mega trials? Have you adopted the new oral factor Xa inhibitors in your practice?
- ARISTOTLE: A major win for apixaban in AF
- Mega JL. A new era for anticoagulation in atrial fibrillation. N Eng J Med 2011; DOI:10.1056/NEJMe1109748. Available here.
- Why has dabigatran uptake been disappointing?